Catalent misses Q1 revenue estimates
By Foo Yun Chee and Maggie Fick BRUSSELS/LONDON (Reuters) -EU antitrust regulators will decide by Dec. 6 whether to clear ...
Reports Q1 revenue $ $1.02B , consensus $1.06B…Q1’25 Adjusted EBITDA of $125 million increased 11% as reported, or 10% in constant ...
And please do keep in touch. … European Union antitrust regulators will decide by Dec. 6 whether to clear Novo Holdings’ ...
The group of like-named companies that include Novo Holdings and Novo Nordisk—the two tied to a multibillion-dollar buyout of ...
Catalent Inc. (CTLT) announced Loss for first quarter that decreased from last year The company's bottom line totaled -$129 million, ...
Roche recently joined naysayers who argue the deal threatens competition in the burgeoning weight loss and diabetes drug ...
The CEO of pharmaceuticals giant Roche said authorities should block the takeover of contract drug manufacturer Catalent by ...
The groups behind the letter alleged that Novo Nordisk’s plant purchases could hinder not only the Danish drugmaker’s chief ...
Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the ...
Roche CEO opposes Novo Nordisk's acquisition of Catalent, citing concerns about competition in the ...
Ardena, a Belgium-based pharmaceutical contract manufacturer, will acquire Catalent’s facility in Somerset, New Jersey, ...
SOMERSET, N.J. (AP) — SOMERSET, N.J. (AP) — Catalent Inc. (CTLT) on Tuesday reported a loss of $129 million in its fiscal first quarter. The Somerset, New Jersey-based company said it had a loss of 71 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback